Biomarkers for immunotherapy in bladder cancer: a moving target

Abstract Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting th...

Full description

Bibliographic Details
Main Authors: David H. Aggen, Charles G. Drake
Format: Article
Language:English
Published: BMJ Publishing Group 2017-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40425-017-0299-1